Literature DB >> 23459476

Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems.

Jae H Hong1, Cornelius J Clancy, Shaoji Cheng, Ryan K Shields, Liang Chen, Yohei Doi, Yanan Zhao, David S Perlin, Barry N Kreiswirth, M Hong Nguyen.   

Abstract

We characterized carbapenem resistance mechanisms among 12 Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (referred to here as KPC K. pneumoniae) clinical isolates and evaluated their effects on the activity of 2- and 3-drug combinations of colistin, doripenem, and ertapenem. All isolates were resistant to ertapenem and doripenem; 75% (9/12) were resistant to colistin. Isolates belonged to the ST258 clonal group and harbored blaKPC-2, blaSHV-12, and blaTEM-1. As determined by time-kill assays, doripenem (8 μg/ml) and ertapenem (2 μg/ml) were inactive against 92% (11/12) and 100% (12/12) of isolates, respectively. Colistin (2.5 μg/ml) exerted some activity (range, 0.39 to 2.5 log10) against 78% (7/9) of colistin-resistant isolates. Colistin-ertapenem, colistin-doripenem, and colistin-doripenem-ertapenem exhibited synergy against 42% (5/12), 50% (6/12), and 67% (8/12) of isolates, respectively. Expression of ompK35 and ompK36 porins correlated with each other (R(2) = 0.80). Levels of porin expression did not correlate with colistin-doripenem or colistin-ertapenem synergy. However, synergy with colistin-doripenem-ertapenem was more likely against isolates with high porin expression than those with low expression (100% [8/8] versus 0% [0/4]; P = 0.002). Moreover, bactericidal activity (area under the bacterial killing curve) against isolates with high porin expression was greater for colistin-doripenem-ertapenem than colistin-doripenem or colistin-ertapenem (P ≤ 0.049). In conclusion, colistin-carbapenem combinations may provide optimal activity against KPC K. pneumoniae, including colistin-resistant isolates. Screening for porin expression may identify isolates that are most likely to respond to a triple combination of colistin-doripenem-ertapenem. In the future, molecular characterization of KPC K. pneumoniae isolates may be a practical tool for identifying effective combination regimens.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23459476      PMCID: PMC3632930          DOI: 10.1128/AAC.02411-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  48 in total

1.  Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa.

Authors:  L Zhang; P Dhillon; H Yan; S Farmer; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

2.  In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.

Authors:  Jimmy Yoon; Carl Urban; Christian Terzian; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 3.  Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.

Authors:  Matthew E Falagas; Sofia K Kasiakou
Journal:  Clin Infect Dis       Date:  2005-03-22       Impact factor: 9.079

4.  Use of a surfactant (polysorbate 80) to improve MIC susceptibility testing results for polymyxin B and colistin.

Authors:  Helio S Sader; Paul R Rhomberg; Robert K Flamm; Ronald N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2012-10-25       Impact factor: 2.803

5.  Rapid microprocedure for isolating detergent-insoluble outer membrane proteins from Haemophilus species.

Authors:  G M Carlone; M L Thomas; H S Rumschlag; F O Sottnek
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

6.  Porin expression in clinical isolates of Klebsiella pneumoniae.

Authors:  Santiago Hernández-Allés; Sebastián Albertí; Dolores Álvarez; Antonio Doménech-Sánchez; Luis Martínez-Martínez; José Gil; Juan M Tomás; Vicente J Benedí
Journal:  Microbiology       Date:  1999-03       Impact factor: 2.777

7.  Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.

Authors:  A C Gales; A O Reis; R N Jones
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

8.  Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium.

Authors:  Simona Bratu; David Landman; Robin Haag; Rose Recco; Antonella Eramo; Maqsood Alam; John Quale
Journal:  Arch Intern Med       Date:  2005-06-27

Review 9.  Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.

Authors:  Jian Li; Roger L Nation; Robert W Milne; John D Turnidge; Kingsley Coulthard
Journal:  Int J Antimicrob Agents       Date:  2005-01       Impact factor: 5.283

10.  Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City.

Authors:  Patricia A Bradford; Simona Bratu; Carl Urban; Melissa Visalli; Noriel Mariano; David Landman; James J Rahal; Steven Brooks; Sanda Cebular; John Quale
Journal:  Clin Infect Dis       Date:  2004-06-14       Impact factor: 9.079

View more
  22 in total

1.  Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.

Authors:  Ghady Haidar; Cornelius J Clancy; Liang Chen; Palash Samanta; Ryan K Shields; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  Predictability of Phenotype in Relation to Common β-Lactam Resistance Mechanisms in Escherichia coli and Klebsiella pneumoniae.

Authors:  Alex Agyekum; Alicia Fajardo-Lubián; Xiaoman Ai; Andrew N Ginn; Zhiyong Zong; Xuejun Guo; John Turnidge; Sally R Partridge; Jonathan R Iredell
Journal:  J Clin Microbiol       Date:  2016-02-24       Impact factor: 5.948

3.  Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing Klebsiella pneumoniae strains with various ompK36 genotypes.

Authors:  Cornelius J Clancy; Binghua Hao; Ryan K Shields; Liang Chen; David S Perlin; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

4.  Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients.

Authors:  C J Clancy; L Chen; R K Shields; Y Zhao; S Cheng; K D Chavda; B Hao; J H Hong; Y Doi; E J Kwak; F P Silveira; R Abdel-Massih; T Bogdanovich; A Humar; D S Perlin; B N Kreiswirth; M Hong Nguyen
Journal:  Am J Transplant       Date:  2013-09-06       Impact factor: 8.086

5.  Sublethal concentrations of carbapenems alter cell morphology and genomic expression of Klebsiella pneumoniae biofilms.

Authors:  Tricia A Van Laar; Tsute Chen; Tao You; Kai P Leung
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

6.  Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.

Authors:  Reem Almaghrabi; Cornelius J Clancy; Yohei Doi; Binghua Hao; Liang Chen; Ryan K Shields; Ellen G Press; Nicole M Iovine; Bethany M Townsend; Marilyn M Wagener; Barry Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

7.  Evaluating Polymyxin B-Based Combinations against Carbapenem-Resistant Escherichia coli in Time-Kill Studies and in a Hollow-Fiber Infection Model.

Authors:  Yiying Cai; Tze-Peng Lim; Jocelyn Qi-Min Teo; Suranthran Sasikala; Eric Chun Yong Chan; Yan Jun Hong; Winnie Lee; Thean Yen Tan; Thuan Tong Tan; Tse Hsien Koh; Li Yang Hsu; Andrea L Kwa
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

Review 8.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

9.  Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia.

Authors:  Ryan K Shields; M Hong Nguyen; Brian A Potoski; Ellen G Press; Liang Chen; Barry N Kreiswirth; Lloyd G Clarke; Gregory A Eschenauer; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

10.  Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections.

Authors:  Ryan K Shields; Erin K McCreary; Rachel V Marini; Ellen G Kline; Chelsea E Jones; Binghua Hao; Liang Chen; Barry N Kreiswirth; Yohei Doi; Cornelius J Clancy; M Hong Nguyen
Journal:  Clin Infect Dis       Date:  2020-07-27       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.